Creso Pharma Targets Multi-Billion Dollar Pet Industry
Ryan Allway
January 16th, 2019
Exclusive, News, Top Story
Global consumers spend billions of dollars on their pets each year, according to GfK, with two-thirds of sales taking place in the United States and Europe. In the U.S. alone, the American Pet Products Association reckons that consumers spent more than $72 billion on their pets in 2018, including about $30 billion on food, $15 billion on supplies and over-the-counter medicine, and $20 billion on veterinary care.
Cannabidiol, or CBD products, have become especially popular as an over-the-counter medicine, and an alternative to prescription medication for pets. While studies in humans have dominated the headlines, an overwhelming number of reports from veterinarians and pet owners have shown that CBD promotes well-being, balances behavior, and reduces tiredness and fatigue. It’s a natural way to help keep pets well-adjusted and ensure their comfort in old age.
In this article, we will look at Creso Pharma Inc. (ASX: CPH) and why it’s well positioned to capitalize on the rapid growth in the pet CBD market.
Click here to receive an investor presentation and a going public alert
First Mover Advantage
There are many companies that have developed CBD products for pets, but many of them have experienced problems. In the United States, the U.S. Food and Drug Administration sent warning letters to several manufacturers regarding product labeling and promises. The same agency sent warning letters to other human-focused CBD product manufacturers, saying that some of their products didn’t contain as much CBD as promised on the label.
Creso Pharma’s anibidiol®is the first Swiss complementary feed for companion animals that contains natural full spectrum hemp oil with CBD. The company’s two products, anibidiol® 2.5 and anibidiol® 8, are already generating revenue across the European Union. With the company’s focus on Swiss quality, the products have already started to generate a strong reputation across Europe that could translate into sales in other markets down the road.
In addition to CBD, anibidiol® contains vitamins niacin and B6, fatty acids Omega 3, 6, and 9, terpenes, flavonoids, and other herbal active ingredients. The product is THC-free (non-detectable) with no reported side-effects, which means that consumers don’t have to worry about harmful or unintended side-effects.
Expansion Beyond Animals
Creso Animal Health is just one of its five businesses focusing on different areas of the cannabis industry, which include therapeutics, nutraceuticals, topicals, and lifestyle products. By bringing pharmaceutical rigor to the cannabis industry, the company aims to manufacture the highest-quality products for both humans and animals through its R&D base in Switzerland and cultivation facilities in Canada and Colombia.
The company’s Mernova Medicinal Inc. subsidiary is a 24,000 sq. ft. purpose-built facility in Canada with initial sales in the country starting next quarter. In 2019, the company plans to build out a GMP compliant, pharmaceutical-grade edible production facility to prepare for the country’s upcoming legalization of edible products. Its other cultivation facilities are located in Colombia and Israel—where it’s pursuing a joint venture.
Along with its cannabis production footprint, the company has developed a wide range of delivery systems for cannabinoids. The company’s focus is on buccal and topical products, which are designed to significantly improve bioavailability and absorption compared to orally-consumed products which need to go through the stomach and are largely destroyed in the passage. Several products have already been launched throughout Switzerland, Europe, and New Zealand.
Click here to receive an investor presentation and a going public alert
Looking Ahead
Creso Pharma Inc. (ASX: CPH) represents a unique opportunity to invest across a broad range of cannabinoid delivery methods and end markets. With its CBD-based animal health products, the company has developed an early edge in Europe that it could exploit to capitalize on the $70+ billion global animal health market. The company’s potential is further underscored by its diverse human product lines spanning key European countries.
For more information, visit the company’s website
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
New You, Inc. (OTCQB: NWYU) wholly-owned subsidiary, ST Brands Corp is a holding company of branded assets that create, develop, market, and sell unique and proprietary cannabidiol (“CBD”) products to various segments of the global consumer market.
AYR Strategies was created as a special purpose acquisition corporation incorporated under the laws of the Province of Ontario that acquired five subsidiaries.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
